
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical's recurring revenue model, bolstered by treatment orders and a growing console base, positions the company for sustained success, particularly as it aligns its sales execution with enterprise needs. The company is on track to expand gross margins through a mix of higher-margin recurring sales, cost reductions from production shifts, and increasing adoption of its Tablo machine, which provides a competitive edge in the dialysis market. Sales are projected to grow from $115 million in 2022 to $127 million by 2025, and reach approximately $191 million by 2028, reflecting a solid long-term growth trajectory driven by ongoing adoption.
Bears say
Outset Medical's Q2 2024 results fell short of consensus expectations, leading to a significant reduction in 2024 revenue guidance from $145-153 million to approximately $110 million, equating to a notable year-over-year decline of 15.6%. The company reported a year-over-year revenue drop of 24% and a slight sequential decline of 2.8%, signaling potential challenges in maintaining growth. Additionally, factors such as slower-than-expected adoption of the Tablo system in acute care settings and increased competition present further risks to revenue growth and overall market position.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares